JP2013519699A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519699A5
JP2013519699A5 JP2012553267A JP2012553267A JP2013519699A5 JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5 JP 2012553267 A JP2012553267 A JP 2012553267A JP 2012553267 A JP2012553267 A JP 2012553267A JP 2013519699 A5 JP2013519699 A5 JP 2013519699A5
Authority
JP
Japan
Prior art keywords
molecule
domain
fviii
another embodiment
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012553267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051959 external-priority patent/WO2011101284A1/en
Publication of JP2013519699A publication Critical patent/JP2013519699A/ja
Publication of JP2013519699A5 publication Critical patent/JP2013519699A5/ja
Withdrawn legal-status Critical Current

Links

JP2012553267A 2010-02-16 2011-02-10 因子viii融合タンパク質 Withdrawn JP2013519699A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153715 2010-02-16
EP10153715.7 2010-02-16
US30617710P 2010-02-19 2010-02-19
US61/306,177 2010-02-19
PCT/EP2011/051959 WO2011101284A1 (en) 2010-02-16 2011-02-10 Factor viii fusion protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016021624A Division JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質

Publications (2)

Publication Number Publication Date
JP2013519699A JP2013519699A (ja) 2013-05-30
JP2013519699A5 true JP2013519699A5 (enExample) 2015-07-02

Family

ID=42244627

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012553267A Withdrawn JP2013519699A (ja) 2010-02-16 2011-02-10 因子viii融合タンパク質
JP2016021624A Expired - Fee Related JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質
JP2017144266A Withdrawn JP2017190342A (ja) 2010-02-16 2017-07-26 因子viii融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016021624A Expired - Fee Related JP6185097B2 (ja) 2010-02-16 2016-02-08 因子viii融合タンパク質
JP2017144266A Withdrawn JP2017190342A (ja) 2010-02-16 2017-07-26 因子viii融合タンパク質

Country Status (5)

Country Link
US (2) US9493543B2 (enExample)
EP (2) EP2536754A1 (enExample)
JP (3) JP2013519699A (enExample)
CN (2) CN105153313A (enExample)
WO (1) WO2011101284A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EA035323B1 (ru) * 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt) * 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
CN104411323A (zh) 2012-04-24 2015-03-11 诺和诺德A/S(股份有限公司) 适用于治疗血友病的药物组合物
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
US9815871B2 (en) 2013-04-23 2017-11-14 President And Fellows Of Harvard College Genetic reprogramming of bacterial biofilms
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. 第viii因子両性イオンポリマーコンジュゲート
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第viii因子製剤
JP6849590B2 (ja) * 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
JP6916524B2 (ja) 2015-04-06 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 機能的タンパク質配列をディスプレイする生合成アミロイドに基づく材料
WO2016198521A1 (en) * 2015-06-10 2016-12-15 Novo Nordisk A/S Fviii fusion proteins
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
JP2018529760A (ja) 2015-08-12 2018-10-11 セル マシン,インコーポレイテッド 長半減期凝固複合体と関連する方法及び組成物
GB201520021D0 (en) * 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11098133B2 (en) 2016-05-19 2021-08-24 President And Fellows Of Harvard College Methods of making gels and films using curli nanofibers
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技(上海)有限公司 双特异性抗体及其制备方法与用途
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CN108623695B (zh) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 一种白蛋白结合肽-人睫状神经营养因子融合蛋白及其制备方法和应用
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
CN113166271A (zh) * 2018-05-18 2021-07-23 郑州晟斯生物科技有限公司 具有延长半衰期的融合多肽缀合物
MA53020A (fr) * 2018-05-18 2021-05-05 Zhengzhou Gensciences Inc Protéine de fusion du fviii améliorée et utilisation associée
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技(上海)有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
JP2022546525A (ja) * 2019-09-02 2022-11-04 ビオテスト・アクチエンゲゼルシャフト 延長された半減期を有する第viii因子タンパク質
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
KR20230074641A (ko) * 2020-09-23 2023-05-30 아블레비아 바이오테크 게엠베하 자가항체-매개 병태의 예방 또는 치료를 위한 화합물
EP4534563A1 (en) * 2022-05-25 2025-04-09 Jiangsu Gensciences Inc. Fviii fusion protein conjugate having extended half-life and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3879395T2 (de) 1987-05-29 1993-06-24 Central Glass Co Ltd Fusionsprotein, enthaltend lymphotoxin.
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US6939677B1 (en) 1990-11-01 2005-09-06 Cancer Research Fund Of Contra Costa Antibody with 46 kdalton HMFG antigen binding specificity, immunoassay kit and diagnostic method
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6524572B1 (en) 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
BRPI0406724A (pt) 2003-01-13 2005-12-20 Macrogenics Inc Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US20070106066A1 (en) 2003-10-28 2007-05-10 Alexander Cherkasky Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
WO2005113584A1 (en) 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
KR20080021590A (ko) 2005-03-24 2008-03-07 네오스 테크놀로지스, 인크. 가용성이고 활성인 진핵생물 글리코실트랜스퍼라제의원핵생물 유기체 내에서의 발현
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1968999A2 (en) * 2005-12-07 2008-09-17 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
WO2007088882A1 (ja) 2006-01-31 2007-08-09 Ishihara Sangyo Kaisha, Ltd. エンベロープウイルスの構成成分に親和性を有するポリペプチドと細胞内物質導入への使用
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン.ヴェー. 血清タンパク質と結合可能なペプチド
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP2124994A2 (en) * 2007-01-23 2009-12-02 Zymogenetics, Inc. Soluble fc gamma r1a for reducing inflammation
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物

Similar Documents

Publication Publication Date Title
JP2013519699A5 (enExample)
JP6559642B2 (ja) Fviiiの特定部位の変更
JP6527918B2 (ja) 第viii因子組成物、ならびに組成物の作製方法および用途
TWI686404B (zh) 重組因子viii蛋白
JP2018104459A (ja) 血友病の治療に適する化合物
JP2017503509A5 (enExample)
JP2019531087A (ja) 高グリコシル化ヒト血液凝固第viii因子の融合タンパク質、その調製方法、および使用
JP2015527882A5 (enExample)
JP6605593B2 (ja) 第viii因子およびフォン・ヴィルブランド因子ペプチドを含む製剤
JP2010202664A (ja) 第viii因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
JP2016522219A (ja) 血友病の治療に適する化合物
JP2015519313A (ja) 血友病の治療に適する医薬組成物
JP2025121974A (ja) Siglec依存的免疫応答をモジュレートするポリペプチド
WO2020063562A1 (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
WO2017050820A1 (en) Fviii fusion proteins
KR20250168493A (ko) 개선된 약동학을 갖는 fviii-vwf 융합 단백질